Madrigal Pharmaceuticals Inc (MDGL)
205.43
-1.72
(-0.83%)
USD |
NASDAQ |
May 10, 16:00
205.43
0.00 (0.00%)
After-Hours: 20:00
Madrigal Pharmaceuticals Cash from Operations (Quarterly): -149.16M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -149.16M |
December 31, 2023 | -79.93M |
September 30, 2023 | -84.92M |
June 30, 2023 | -75.31M |
March 31, 2023 | -84.07M |
December 31, 2022 | -58.52M |
September 30, 2022 | -59.07M |
June 30, 2022 | -57.36M |
March 31, 2022 | -49.91M |
December 31, 2021 | -48.05M |
September 30, 2021 | -45.56M |
June 30, 2021 | -46.88M |
March 31, 2021 | -43.43M |
December 31, 2020 | -54.95M |
September 30, 2020 | -47.85M |
June 30, 2020 | -24.26M |
March 31, 2020 | -30.51M |
December 31, 2019 | -12.28M |
September 30, 2019 | -11.32M |
June 30, 2019 | -11.54M |
March 31, 2019 | -6.478M |
December 31, 2018 | -6.265M |
September 30, 2018 | -5.238M |
June 30, 2018 | -5.36M |
March 31, 2018 | -8.644M |
Date | Value |
---|---|
December 31, 2017 | -5.945M |
September 30, 2017 | -4.951M |
June 30, 2017 | -7.65M |
March 31, 2017 | -3.771M |
December 31, 2016 | -5.28M |
September 30, 2016 | -9.243M |
June 30, 2016 | -2.647M |
March 31, 2016 | -0.438M |
December 31, 2015 | -1.096M |
September 30, 2015 | 34.46M |
June 30, 2015 | -17.73M |
March 31, 2015 | -18.78M |
December 31, 2014 | -19.22M |
September 30, 2014 | -18.57M |
June 30, 2014 | -20.87M |
March 31, 2014 | -20.27M |
December 31, 2013 | -18.69M |
September 30, 2013 | -16.59M |
June 30, 2013 | -19.92M |
March 31, 2013 | -22.21M |
December 31, 2012 | -12.52M |
September 30, 2012 | -13.26M |
June 30, 2012 | -13.10M |
March 31, 2012 | -15.25M |
December 31, 2011 | -10.49M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-149.16M
Minimum
Mar 2024
-11.32M
Maximum
Sep 2019
-53.74M
Average
-48.98M
Median
Cash from Operations (Quarterly) Benchmarks
Eli Lilly and Co | 1.166B |
Viking Therapeutics Inc | -6.134M |
Akero Therapeutics Inc | -48.63M |
89bio Inc | -34.29M |
Geron Corp | -62.25M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | 98.05M |
Cash from Financing (Quarterly) | 573.71M |
Free Cash Flow | -391.12M |
Free Cash Flow Per Share (Quarterly) | -7.475 |
Free Cash Flow Yield | -9.95% |